Objective: To compare the autoantigenicity of the recently described N-terminally elongated PM-Scl-75 protein with that of PM-Scl-100 and the originally defined PM-Scl-75 polypeptide, and to determine its value for analyzing sera from patients with the polymyositis (PM)/scleroderma overlap syndrome.
Methods: Serum samples obtained from patients with the PM/scleroderma overlap syndrome and from patients with several other diseases were analyzed for the presence of autoantibodies reactive with recombinant PM-Scl-100 and PM-Scl-75 (both the original and the longer form) proteins, in an enzyme-linked immunosorbent assay (ELISA).
Results: Autoantibodies recognizing the longer PM-Scl-75 protein isoform were detected in 28% of the patients with PM/scleroderma. This percentage is slightly higher than that for PM-Scl-100 (25%) and is significantly higher than that for the previously defined PM-Scl-75 protein (11%). In addition, we identified a significant number of patients who had anti-PM-Scl-75 but not anti-PM-Scl-100 antibodies. This finding contrasts with what has been previously reported for the shorter version of the PM-Scl-75 protein.
Conclusion: Our data indicate that use of the long PM-Scl-75 isoform in addition to PM-Scl-100 in ELISAs significantly increases the number of patients in whom anti-PM-Scl autoantibodies can be detected.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.20056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autoantibody-Based Clinicoradiopathologic Phenotyping of Idiopathic Inflammatory Myopathies: An Indian Cohort.
J Clin Neuromuscul Dis
December 2024
Department of Neurology.
Objectives: We aim to characterize the clinical, pathological, laboratory and imaging features of various antibody defined IIM subgroups in Indian population.
Methodology: 103 patients who satisfied 2017 ACR/ EULAR Classification criteria for IIM, and tested seropositive for myositis antibodies using Immunoblot technique were retrospectively identified. Patients were classified into following subgroups - Mi2B group, SRP group, Anti RNA Synthetase antibody group (Jo 1, PL 7, PL 12, OJ), multiple MSA, only MAA group (U1RNP, Ro 52, SS-A, SS-B, PM Scl 75, PM Scl 100).
Prevalence of anti-synthetase antibodies among systemic sclerosis patients.
Eur J Intern Med
November 2023
Department of Internal Medicine E, Meir Medical Center, Kfar Saba 4428164, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: we aimed to estimate the prevalence of Amino acyl-transfer ribonucleic acid synthetase antibodies (Anti-ARS); myositis specific antibodies, among patients with systemic sclerosis (SSc), to evaluate the clinical associations of anti-ARS antibodies in SSc patients and to identify risk factors for development of interstitial lung disease (ILD) in SSc.
Methods: A prospective study of 71 systemic sclerosis patients in our rheumatology clinic in Israel. Sera were tested for myositis antibodies.
Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies.
Immunol Res
October 2023
UOC Laboratorio Patologia Clinica, Policlinico S. Maria Alle Scotte, AOU Senese, Siena, Italy.
The presence of interstitial lung disease (ILD) is a common and fearsome feature of idiopathic inflammatory myopathies (IIM). Such patients show radiological pattern of non-specific interstitial pneumonia (NSIP). The present study aimed to assess the prevalence of myositis-specific and myositis-associated antibodies (MSA and MAA) in a cohort of patients with a previous diagnosis of NSIP and no sign or symptom of IIM.
View Article and Find Full Text PDFDiagnostic accuracy and predictive value of autoantibody profiles in patients with systemic sclerosis: a single-center study.
Clin Rheumatol
May 2023
Department of Rheumatology and Immunology, Peking University People's Hospital, No.11 Xizhimen South St., Beijing, 100044, China.
Objective: To determine diagnostic accuracy and evaluate the predictive value of autoantibody profiles in patients with systemic sclerosis (SSc).
Methods: A total of 140 patients with SSc (125 female, mean age 54.2 ± 14.
Screening and characterization of myositis-related autoantibodies in COVID-19 patients.
Clin Transl Sci
January 2023
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Article Synopsis
- - An effective immune response is essential for managing and overcoming COVID-19, but severe cases often show signs of autoimmunity, resembling conditions like inflammatory myopathy and rapidly progressive interstitial lung disease (ILD).
- - In a study of 25 COVID-19 patients with varying symptoms, 36% were found to have autoantibodies related to myositis, with specific antigens identified using line blot analysis, although these antibodies did not correlate with illness severity.
- - To accurately identify and categorize autoantibodies in COVID-19 patients, the study emphasizes using multiple testing methods, as relying on a single method could lead to incorrect conclusions regarding autoimmune disease diagnoses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!